Business
Contract win and contract extension
IXICO plc has secured new business and contract extensions valued at £1.3 million over two years, bolstering its position in neurological disorder research. The company will provide amyloid PET imaging analytics to validate a new Alzheimer's Disease blood-based biomarker test, aiming for FDA clearance, and has extended a Phase 2 Huntington's Disease clinical trial contract by adding three new analysis methodologies. These developments align with IXICO's growth strategy, deepening its impact in Alzheimer's and maintaining leadership in Huntington's disease research while advancing towards higher-value clinical development work. Disclaimer*
About this update from Ixico Plc
IXICO plc ("IXICO", the "Company" or the "Group") Alzheimer's contract win and Phase 2 clinical trial contract extension with total value of £1.3 million 21 May 2026, IXICO plc (AIM: IXI) - London, UK. IXICO, a global leader in neuroscience imaging and biomarker analytics, using its AI-driven platform to help advance drug and diagnostics development in neurological disorders, today announced a contract win and contract extension with a total value of £1.3 million over 2 years. Blood based biomarker validation contract IXICO will provide amyloid PET imaging analytics to validate a new Alzheimer's Disease (AD) blood-based biomarker test for a global diagnostics and life sciences company with the aim of facilitating FDA regulatory clearance. Phase 2 contract extension This extends an existing Phase 2 Huntington's Disease (HD) clinical trial contract with a leading global pharmaceutical company, expanding the existing analysis methodologies with three additional analysis approaches. Bram Goorden, Chief Executive Officer of IXICO, commented: "These latest contract wins are first and foremost important for progress in research and patient care. They also fit squarely in the growth strategy for our company, hitting three key components of the plan: deepening impact in broader CNS areas such as AD while maintaining leadership in rare neurodegenerative disease areas like HD, enabling novel modalities and moving toward high-value later stage clinical development work. It is deeply satisfying to see an increasing number of clients recognise IXICO's leading role in the field of CNS precision medicine". The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the UK version of the EU Market Abuse Regulation 596/2014 which is part of UK law by virtue of the European Union (Withdrawal) Act 2018, as amended and supplemented from time to time. Upon the publication of this announcement, this inside information is now considered to be in the public domain. Ends For further information please contact: IXICO plc +44 (0) 20 3763 7499 Grant Nash, Chief Financial Officer James Chandler, Chief Business Officer Cavendish Capital Markets Limited (Nominated Adviser and Sole Broker) +44 (0) 20 7220 0500 Giles Balle...